Dennis E. Hruby

Q: What Schools Are Affiliated With Dennis E. Hruby

Dennis E. Hruby is affiliated with the following schools: University of Alabama, Oregon State University

Dennis E. Hruby's AcademicInfluence.com Rankings

Dennis E. Hruby

Philosophy

#9230

World Rank

#12759

Historical Rank

Logic

#6218

World Rank

#7713

Historical Rank

philosophy Degrees

Dennis E. Hruby

Biology

#12672

World Rank

#16163

Historical Rank

Virology

#308

World Rank

#315

Historical Rank

Microbiology

#754

World Rank

#830

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Dennis E. Hruby's Degrees

PhD Microbiology University of California, Berkeley
Doctorate Medicine University of California, San Francisco

Why Is Dennis E. Hruby Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Dennis E. Hruby's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Clinical features and management of human monkeypox: a retrospective observational study in the UK (2022) (532)
Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein (1992) (325)
An Orally Bioavailable Antipoxvirus Compound (ST-246) Inhibits Extracellular Virus Formation and Protects Mice from Lethal Orthopoxvirus Challenge (2005) (315)
Severe eczema vaccinatum in a household contact of a smallpox vaccinee. (2008) (183)
Oral Tecovirimat for the Treatment of Smallpox (2018) (166)
Vaccinia Virus Replication I. Requirement for the Host-Cell Nucleus (1979) (152)
Yeast KEX2 endopeptidase correctly cleaves a neuroendocrine prohormone in mammalian cells. (1988) (145)
Neomycin resistance as a dominant selectable marker for selection and isolation of vaccinia virus recombinants (1985) (131)
Nonhuman Primates Are Protected from Smallpox Virus or Monkeypox Virus Challenges by the Antiviral Drug ST-246 (2009) (125)
Identification of a Broad-Spectrum Arenavirus Entry Inhibitor (2008) (121)
Chlamydia psittaci IncA is phosphorylated by the host cell and is exposed on the cytoplasmic face of the developing inclusion (1997) (115)
A Novel Inhibitor of Dengue Virus Replication That Targets the Capsid Protein (2012) (114)
Pox proteomics: mass spectrometry analysis and identification of Vaccinia virion proteins (2006) (112)
Processing and secretion of nerve growth factor: expression in mammalian cells with a vaccinia virus vector (1988) (111)
Efficacy of Delayed Treatment with ST-246 Given Orally against Systemic Orthopoxvirus Infections in Mice (2006) (106)
Inactivation of the srtA Gene inStreptococcus gordonii Inhibits Cell Wall Anchoring of Surface Proteins and Decreases In Vitro and In Vivo Adhesion (2001) (102)
Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses (2005) (99)
Synergistic Efficacy of the Combination of ST-246 with CMX001 against Orthopoxviruses (2007) (97)
ST-246 Antiviral Efficacy in a Nonhuman Primate Monkeypox Model: Determination of the Minimal Effective Dose and Human Dose Justification (2009) (93)
Conditional lethal expression of the vaccinia virus L1R myristylated protein reveals a role in virion assembly (1994) (91)
Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. (2007) (86)
Interaction of GRASP, a Protein encoded by a Novel Retinoic Acid-induced Gene, with Members of the Cytohesin Family of Guanine Nucleotide Exchange Factors* (2000) (85)
The multistep proteolytic maturation pathway utilized by vaccinia virus P4a protein: a degenerate conserved cleavage motif within core proteins. (1991) (83)
Escherichia coli DegP Protease Cleaves between Paired Hydrophobic Residues in a Natural Substrate: the PapA Pilin (2002) (83)
Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. (2012) (81)
Mapping and identification of the vaccinia virus thymidine kinase gene (1982) (81)
Expression of Sindbis virus structural proteins via recombinant vaccinia virus: synthesis, processing, and incorporation into mature Sindbis virions (1985) (80)
Listeria monocytogenes 10403S HtrA Is Necessary for Resistance to Cellular Stress and Virulence (2006) (80)
Conserved DegP Protease in Gram-Positive Bacteria Is Essential for Thermal and Oxidative Tolerance and Full Virulence inStreptococcus pyogenes (2001) (76)
Fine structure analysis and nucleotide sequence of the vaccinia virus thymidine kinase gene. (1983) (76)
Novel Benzoxazole Inhibitor of Dengue Virus Replication That Targets the NS3 Helicase (2013) (72)
Activity of the Anti-Orthopoxvirus Compound ST-246 against Vaccinia, Cowpox and Camelpox Viruses in Cell Monolayers and Organotypic Raft Cultures (2007) (71)
Vaccination of BALB/c Mice with Escherichia coli-Expressed Vaccinia Virus Proteins A27L, B5R, and D8L Protects Mice from Lethal Vaccinia Virus Challenge (2008) (70)
The Vaccinia Virus I7L Gene Product Is The Core Protein Proteinase (2002) (70)
In Vitro Efficacy of ST246 against Smallpox and Monkeypox (2008) (69)
Proteolytic maturation of vaccinia virus core proteins: identification of a conserved motif at the N termini of the 4b and 25K virion proteins. (1991) (68)
Expression and cell type--specific processing of human preproenkephalin with a vaccinia recombinant. (1986) (67)
Development of ST-246® for Treatment of Poxvirus Infections (2010) (66)
Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. (2008) (66)
Effective Antiviral Treatment of Systemic Orthopoxvirus Disease: ST-246 Treatment of Prairie Dogs Infected with Monkeypox Virus (2011) (66)
Efficacy of Tecovirimat (ST-246) in Nonhuman Primates Infected with Variola Virus (Smallpox) (2013) (65)
A tandemly-oriented late gene cluster within the vaccinia virus genome. (1986) (64)
Insertional inactivation of the large subunit of ribonucleotide reductase encoded by vaccinia virus is associated with reduced virulence in vivo. (1990) (63)
Development of the small-molecule antiviral ST-246 as a smallpox therapeutic. (2011) (63)
Single-Dose Safety and Pharmacokinetics of ST-246, a Novel Orthopoxvirus Egress Inhibitor (2008) (62)
Palmitylation of the Vaccinia Virus 37-kDa Major Envelope Antigen (1997) (61)
An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications (2020) (61)
Control of expression of the vaccinia virus thymidine kinase gene (1981) (58)
Progressive vaccinia in a military smallpox vaccinee - United States, 2009. (2009) (57)
Oral Immunization with RecombinantStreptococcus gordonii Expressing Porphyromonas gingivalis FimA Domains (2001) (57)
The vaccinia virus 4c and A-type inclusion proteins are specific markers for the intracellular mature virus particle (1996) (56)
Encephalomyocarditis virus RNA. III. Presence of a genome-associated protein (1978) (55)
Identification and analysis of three myristylated vaccinia virus late proteins (1997) (54)
Cellular differences in the molecular mechanisms of vaccinia virus host range restriction. (1980) (53)
Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge (2019) (52)
Use of a cell-free system to identify the vaccinia virus L1R gene product as the major late myristylated virion protein M25 (1990) (51)
Treatment with the Smallpox Antiviral Tecovirimat (ST-246) Alone or in Combination with ACAM2000 Vaccination Is Effective as a Postsymptomatic Therapy for Monkeypox Virus Infection (2015) (51)
Nucleotide sequence and molecular genetic analysis of the large subunit of ribonucleotide reductase encoded by vaccinia virus. (1988) (50)
Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesis (2009) (49)
Vaccinia virus vectors: new strategies for producing recombinant vaccines (1990) (49)
Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice (2009) (49)
ST-246 Inhibits In Vivo Poxvirus Dissemination, Virus Shedding, and Systemic Disease Manifestation (2009) (48)
New Class of Orthopoxvirus Antiviral Drugs That Block Viral Maturation (2004) (48)
ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for orthopoxvirus wrapping (2015) (47)
Differential utilization of a conserved motif for the proteolytic maturation of vaccinia virus proteins. (1994) (47)
N-(3,3a,4,4a,5,5a,6,6a-Octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol-2-(1H)-yl)carboxamides: Identification of novel orthopoxvirus egress inhibitors. (2007) (47)
Vaccinia virus replication requires active participation of the host cell transcriptional apparatus. (1979) (46)
Effects of Treatment Delay on Efficacy of Tecovirimat Following Lethal Aerosol Monkeypox Virus Challenge in Cynomolgus Macaques (2018) (44)
Encephalomyocarditis virus RNA: variations in polyadenylic acid content and biological activity (1976) (44)
Clinical and Microbiological Responses of Volunteers to Combined Intranasal and Oral Inoculation with a Streptococcus gordonii Carrier Strain Intended for Future Use as a Group A Streptococcus Vaccine (2005) (43)
Cell-free synthesis of enzymatically active vaccinia virus thymidine kinase. (1981) (43)
The Vaccinia Virus F13L YPPL Motif Is Required for Efficient Release of Extracellular Enveloped Virus (2007) (43)
Characterization of the vaccinia virus L1R myristylprotein as a component of the intracellular virion envelope. (1994) (42)
Safety and Pharmacokinetics of the Anti-Orthopoxvirus Compound ST-246 following a Single Daily Oral Dose for 14 Days in Human Volunteers (2012) (41)
Identification and analysis of vaccinia virus palmitylproteins. (2000) (40)
Immunolocalization of vaccinia virus structural proteins during virion formation. (1994) (40)
Gene transfer techniques to study neuropeptide processing. (1988) (39)
Discovery of small molecule inhibitors of ubiquitin-like poxvirus proteinase I7L using homology modeling and covalent docking approaches (2007) (39)
Molecular Dissection of the Vaccinia Virus I7L Core Protein Proteinase (2003) (38)
Safety and Pharmacokinetics of the Antiorthopoxvirus Compound ST-246 following Repeat Oral Dosing in Healthy Adult Subjects (2010) (38)
Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox – An animal model of smallpox (2012) (37)
Fatty acid acylation of vaccinia virus proteins (1989) (37)
Nucleotide sequence and transcript organization of a region of the vaccinia virus genome which encodes a constitutively expressed gene required for DNA replication (1987) (36)
Identification of the ATP-binding domain of vaccinia virus thymidine kinase. (1990) (36)
A transcriptionally controlled trans-processing assay: putative identification of a vaccinia virus-encoded proteinase which cleaves precursor protein P25K (1994) (35)
The Vaccinia Virus G1L Putative Metalloproteinase Is Essential for Viral Replication In Vivo (2004) (34)
Brefeldin A inhibits vaccinia virus envelopment but does not prevent normal processing and localization of the putative envelopment receptor P37. (1995) (34)
SAR analysis of a series of acylthiourea derivatives possessing broad-spectrum antiviral activity. (2012) (33)
Immunisation of cattle with a recombinant togavirus-vaccinia virus strain. (1985) (33)
Site-directed mutagenesis of a conserved domain in vaccinia virus thymidine kinase. Evidence for a potential role in magnesium binding. (1992) (33)
Vaccinia virus proteolysis—a review (2006) (32)
Discovery and optimization of potent broad-spectrum arenavirus inhibitors derived from benzimidazole. (2013) (30)
Rifampicin prevents virosome localization of L65, an essential vaccinia virus polypeptide. (1989) (30)
Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination (2007) (30)
Expression of functional Porphyromonas gingivalis fimbrillin polypeptide domains on the surface of Streptococcus gordonii (1996) (27)
Viral acylproteins: greasing the wheels of assembly. (1993) (27)
Chlamydial development is blocked in host cells transfected with Chlamydophila caviae incA (2004) (27)
A conditional-lethal vaccinia virus mutant demonstrates that the I7L gene product is required for virion morphogenesis (2005) (26)
A single amino acid substitution abolishes feedback inhibition of vaccinia virus thymidine kinase. (1992) (26)
Transcriptional and translational analysis of the vaccinia virus late gene L65 (1985) (25)
Proteolytic cleavage of vaccinia virus virion proteins. Mutational analysis of the specificity determinants. (1994) (25)
trans processing of vaccinia virus core proteins (1993) (25)
An NH2-terminal peptide from the vaccinia virus L1R protein directs the myristylation and virion envelope localization of a heterologous fusion protein. (1993) (25)
Analysis of a Vaccinia Virus Mutant Expressing a Nonpalmitylated Form of p37, a Mediator of Virion Envelopment (1998) (25)
Nucleotide sequence and molecular genetic analysis of the vaccinia virus HindIII N/M region encoding the genes responsible for resistance to α-Amanitin (1988) (25)
Isolation of vaccinia virus mutants capable of replicating independently of the host cell nucleus (1984) (24)
Smallpox antiviral drug development: satisfying the animal efficacy rule (2006) (24)
Use of vaccinia virus as a neuropeptide expression vector. (1986) (24)
Posttranslational modification of vaccinia virus proteins. (1990) (23)
Specific Targeting of the F13L Protein by St-246 Affects Orthopoxvirus Production Differently (2008) (23)
Evidence for multiple species of vaccinia virus-encoded palmitylated proteins. (1992) (22)
Inhibition of vaccinia virus thymidine kinase by the distal products of its own metabolic pathway. (1985) (22)
Translation of black beetle virus RNA and heterologous viral RNAs in cell-free lysates derived from Drosophila melanogaster (1981) (22)
Noncoordinate regulation of a vaccinia virus late gene cluster (1987) (21)
Nucleotide sequence of the Escherichia coli thymidine kinase gene provides evidence for conservation of functional domains and quaternary structure (1991) (21)
Expression of streptococcal M protein in mammalian cells. (1988) (20)
Quaternary structure of vaccinia virus thymidine kinase (1990) (20)
Discovery and optimization of potent broad-spectrum arenavirus inhibitors derived from benzimidazole and related heterocycles. (2013) (19)
Analysis of Factors Affecting Surface Expression and Immunogenicity of Recombinant Proteins Expressed by Gram-Positive Commensal Vectors (2002) (19)
Molecular dissection of cis-acting regulatory elements from 5'-proximal regions of a vaccinia virus late gene cluster (1988) (19)
Lead optimization of an acylhydrazone scaffold possessing antiviral activity against Lassa virus. (2013) (18)
A trans-Golgi Network Resident Protein, golgin-97, Accumulates in Viral Factories and Incorporates into Virions during Poxvirus Infection (2006) (18)
Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice. (2010) (18)
An ATP-dependent inhibition of protein synthesis in ascites cell extracts by wheat germ protein. (1977) (17)
Comparison of the Safety and Pharmacokinetics of ST-246® after IV Infusion or Oral Administration in Mice, Rabbits and Monkeys (2011) (17)
Secretion ofPorphyromonas gingivalisFimbrillin Polypeptides by RecombinantStreptococcus gordonii (1997) (17)
Biology of vaccinia virus acylproteins. (1998) (17)
Identification of a virus-specified protein in the nucleus of vaccinia virus-infected cells. (1980) (17)
Discovery and development of antiviral drugs for biodefense: Experience of a small biotechnology company (2007) (17)
Pharmacokinetic Comparison of a Single Oral Dose of Polymorph Form I versus Form V Capsules of the Antiorthopoxvirus Compound ST-246 in Human Volunteers (2012) (17)
Biological consequences of antigen and cytokine co-expression by recombinant Streptococcus gordonii vaccine vectors. (2002) (17)
Development of an in vitro cleavage assay system to examine vaccinia virus I7L cysteine proteinase activity (2005) (16)
Inhibition of ovalbumin mRNA translation by 7-methylguanosine-5'-phosphate. (1976) (16)
A single nucleotide substitution in the 5'-untranslated region of the vaccinia N2L gene is responsible for both alpha-amanitin-resistant and temperature-sensitive phenotypes. (1991) (16)
Inhibition of vaccinia virus replication by nicotinamide: evidence for ADP-ribosylation of viral proteins. (1988) (16)
Construction of Recombinant Vaccinia Virus (2004) (16)
Encephalomyocarditis virus RNA. II. Polyadenylic acid requirement for efficient translation (1977) (16)
The Broad-Spectrum Antiviral Compound ST-669 Restricts Chlamydial Inclusion Development and Bacterial Growth and Localizes to Host Cell Lipid Droplets within Treated Cells (2014) (15)
Vaccinia virus: a versatile tool for molecular biologists. (1990) (15)
Deletion of the vaccinia virus F13L gene results in a highly attenuated virus that mounts a protective immune response against subsequent vaccinia virus challenge. (2012) (15)
Resistance to a Novel Antichlamydial Compound Is Mediated through Mutations in Chlamydia trachomatis secY (2012) (15)
Mapping the genomic location of the gene encoding alpha-amanitin resistance in vaccinia virus mutants (1986) (14)
Conditional expression of vaccinia virus genes in mammalian cell lines expressing the tetracycline repressor. (2004) (14)
Construction of recombinant vaccinia virus: cloning into the thymidine kinase locus. (2004) (14)
Novel acylation of poxvirus A-type inclusion proteins. (1999) (13)
Use of a fluorescent chloramphenicol derivative as a substrate for CAT assays. (1990) (13)
Pharmacokinetic and Pharmacodynamic Modeling To Determine the Dose of ST-246 To Protect against Smallpox in Humans (2012) (13)
Expression of saliva-binding epitopes of the Porphyromonas gingivalis FimA protein on the surface of Streptococcus gordonii. (1999) (12)
Pharmacokinetics and Interspecies Allometric Scaling of ST-246, an Oral Antiviral Therapeutic for Treatment of Orthopoxvirus Infection (2013) (12)
Expression and single-step purification of enzymatically active vaccinia virus thymidine kinase containing an engineered oligohistidine domain by immobilized metal affinity chromatography. (1993) (12)
New targets for antibiotic development: biogenesis of surface adherence structures (1998) (12)
Isolation and characterization of mRNA from Paramecium aurelia. (1977) (12)
Expression of recombinant vaccinia virus-derived alphavirus proteins in mosquito cells. (1985) (12)
Association of non-viral proteins with recombinant vaccinia virus virions (2005) (12)
Effect of polyadenylic acid on the functional half-life of encephalomyocarditis virus RNA during translation. (1978) (11)
Surface Expression of the Conserved C Repeat Region of Streptococcal M6 Protein within the Pip Bacteriophage Receptor ofLactococcus lactis (2001) (11)
Protection against streptococcal pharyngeal colonization with vaccines composed of M protein conserved regions. (1991) (11)
Uses of vaccinia virus in vaccine delivery. (1994) (11)
Tecovirimat for smallpox infections. (2010) (11)
A host cell membrane protein, golgin-97, is essential for poxvirus morphogenesis. (2007) (11)
Mass Spectrometry Analysis of Synthetically Myristoylated Peptides (2004) (11)
Analysis of the site occupancy constraints of primary amino acid sequences in the motif directing palmitylation of the vaccinia virus 37-kDa envelope protein. (1999) (10)
Use of fluorescent chloramphenicol derivative as a substrate for chloramphenicol acetyltransferase assays. (1992) (10)
Expression of active monomeric and dimeric nuclease A from the gram-positive Streptococcus gordonii surface protein expression system. (2000) (10)
Mutational analysis of the potential catalytic residues of the VV G1L metalloproteinase (2006) (10)
Expression and regulation of the vaccinia virus thymidine kinase gene in non-permissive cells. (1985) (10)
Expression vector pT7:TKII for the synthesis of authentic biologically active RNA encoding vaccinia virus thymidine kinase. (1989) (10)
Increased susceptibility of Cantagalo virus to the antiviral effect of ST-246®. (2013) (9)
Sequence-independent acylation of the vaccinia virus A-type inclusion protein. (2004) (9)
Nucleotide sequence and molecular genetic analysis of the vaccinia virus HindIII N/M region encoding the genes responsible for resistance to alpha-amanitin. (1988) (9)
Analysis of the role of the amino-terminal peptide of vaccinia virus structural protein precursors during proteolytic processing. (1995) (9)
Isolation and analysis of vaccinia virus previrions (1993) (9)
Use of the gene encoding neomycin phosphotransferase II to convect linked markers into the vaccinia virus genome. (1988) (9)
Physical and molecular genetic analysis of the multistep proteolytic maturation pathway utilized by vaccinia virus P4a protein. (1995) (9)
Secretion of Porphyromonas gingivalis fimbrillin polypeptides by recombinant Streptococcus gordonii. (1997) (8)
Tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations (2022) (8)
Present and future applications of vaccinia virus as a vector. (1988) (8)
Commensal bacteria as a novel delivery system for subunit vaccines directed against agents of bioterrorism (2005) (8)
BiZyme: a novel fusion protein-mediating selection of vaccinia virus recombinants by fluorescence and antibiotic resistance. (2002) (8)
Quantitative assay of recombinant vaccinia virus-encoded neomycin phosphotransferase in infected eukaryotic cell lysates. (1987) (8)
Construction of recombinant vaccinia virus strains using single-stranded DNA insertion vectors. (1986) (7)
SPEX, a system for the expression of recombinant proteins from gram-positive bacterial vectors. (1998) (7)
DNA sequences that regulate expression of a vaccinia virus late gene (L65) and interact with a DNA-binding protein from infected cells (1989) (7)
Construction of a recombinant vaccinia virus which expresses immunoreactive plant virus proteins. (1986) (7)
Vaccinia virus A12L protein and its AG/A proteolysis play an important role in viral morphogenic transition (2007) (7)
Viral proteinases: targets of opportunity (2006) (7)
Importance of disulphide bonds for vaccinia virus L1R protein function (2005) (7)
Development of a radioactive protein A-based assay for analysis of surface protein expression in gram-positive bacteria (1997) (6)
Analysis of vaccinia virus temperature-sensitive I7L mutants reveals two potential functional domains (2006) (6)
Antiviral options for biodefense. (2013) (6)
Tecovirimat is highly efficient on the Monkeypox virus lineage responsible for the international 2022 outbreak (2022) (6)
Synthesis of vaccinia virus thymidine kinase in microinjected Xenopus oocytes. (1982) (6)
Cell-free translation of a chimeric eucaryotic-procaryotic message yields functional chloramphenicol acetyltransferase. (1987) (6)
Expression and purification of histidine-tagged proteins from the gram-positive Streptococcus gordonii SPEX system. (2000) (6)
Streptococcus gordonii Strains Resistant to Fluorodeoxyuridine Contain Mutations in the Thymidine Kinase Gene and Are Deficient in Thymidine Kinase Activity (2000) (5)
Identification of an intragenic integration site for foreign gene expression in recombinant Streptococcus gordonii strains (2001) (5)
Novel codon utilization within the vaccinia virus thymidine kinase gene. (1984) (5)
Comparison of transformation protocols in Streptococcus gordonii and evaluation of native promoter strength using a multiple-copy plasmid. (2007) (5)
Site-directed Mutagenesis of a Conserved Domain in Vaccinia Virus Thymidine Kinase (2001) (5)
Studies on the genomic organization of recombinant Streptococcus gordonii and the development of a novel intergenic integration site for foreign gene expression. (2001) (5)
Development of PLEX, a plasmid-based expression system for production of heterologous gene products by the gram-positive bacteria Streptococcus gordonii. (2005) (4)
Preliminary Screening and In Vitro Confirmation of Orthopoxvirus Antivirals. (2019) (4)
Use of Vaccinia Virus to Express Biopharmaceutical Products (1987) (4)
Finestructure analysis andnucleotide sequence ofthevaccinia virus thymidine kinase gene (1983) (3)
Assembly and analysis of a functional vaccinia virus "amplicon" containing the C-repeat region from the M protein of Streptococcus pyogenes. (1991) (3)
Successful Treatment in the Monkeypox and Variola Primate Models of Smallpox by the Oral Drug ST-246 (2007) (3)
Anchoring a vaccinia virus promoter in the nucleus prevents itstrans-activation by viral infection (1990) (2)
Preparation of a large hydrophobic protein for mass spectrometry analysis: vaccina virus ATI protein. (2003) (2)
Reproductive toxicology. m-/p-cresol. (1997) (2)
Antiviral Potency of ST-246 on the Production of Enveloped Orthopoxviruses and Characterization of ST-246 Resistant Vaccinia, Cowpox and Camelpox Viruses (2008) (2)
Detection of recombinant protein based on reporter enzyme activity: chloramphenicol acetyltransferase. (1997) (2)
Vaccinia Virus Cysteine Proteinase (2013) (1)
A trans-Golgi Network Resident Protein, golgin-97, Accumulates in Viral Factories and Incorporates into Virions during Poxvirus Infection (2007) (1)
The Combination of Anti-poxvirus Compounds ST-246 and TTP-018 are Synergistic In Vitro (2007) (1)
[4] Construction and use of recombinant vaccinia virus vectors (1995) (1)
Discovery of Novel Small Molecule Inhibitors of Dengue Virus Replication (2007) (1)
A single-stranded insertion vector (SSIV) for introducing foreign genes into the vaccinia virus genome. (1987) (1)
Vaccinia Virus Metalloproteinase (2004) (1)
Protection against Streptococcal Mucosal Colonization (1992) (1)
Combinations of 5-Iodo-4′-thio-2′-deoxyuridine and ST-246 or CMX001 Synergistically Inhibit Orthopoxvirus Replication In Vitro (2009) (1)
Less Is More: Poxvirus Proteolysis (2006) (1)
∆F13L-GFP-Vac (p37-deleted vaccinia virus) is attenuated in mice and protects against infection with wild-type virus (2006) (0)
antivirals for treatment of an infection drugs arenaviruses (2008) (0)
Establishment of a Cell-based HTS System for Discovery of Anti-Flavivirus Drugs (2008) (0)
Smallpox Antiviral Drug (2006) (0)
Title : Replication of Vaccinia Virus in the Presence of 1 , 10-phenanthroline (2012) (0)
Synergistic Efﬁcacy of the Combination of ST-246 with CMX001 against Orthopoxviruses (cid:1) (2007) (0)
[8] – Use of Fluorescent Chloramphenicol Derivative as a Substrate for Chloramphenicol Acetyltransferase Assays (1995) (0)
The Vaccinia Virus F13L YPPL Motif Is Required for Efﬁcient Release of Extracellular Enveloped Virus (cid:1) (2007) (0)
Specific inhibition of Orthopoxvirus replication by small interfering RNA: involvement in the mechanism of action of ST-246 (2007) (0)
To Protect against Smallpox in Humans Modeling To Determine the Dose of ST-246 Pharmacokinetic and Pharmacodynamic (2014) (0)
DNA-Binding Protein from Infected Cellst (0)
Characterization of a binding factor that interacts with the sequences upstream of the vaccinia virus thymidine kinase gene (1988) (0)
HelicaseReplication That Targets the NS3 Novel Benzoxazole Inhibitor of Dengue (2014) (0)
Nucleotide sequence and transcriptional studies of the vaccinia virusKpnI I DNA fragment (1989) (0)
Novel Small Molecule Inhibitors of Dengue Virus Replication (2009) (0)
Screening for vaccinia virus egress inhibitors: separation of IMV, IEV, and EEV. (2012) (0)
A simple sequencing gel-saving tip. (1989) (0)
Safety and Pharmacokinetics of the Antiorthopoxvirus Compound ST-246 following Repeat Oral Dosing in Healthy Adult Subjects (cid:1) (2010) (0)
Efficacy of Delayed Therapy Using Combinations of ST-246 with CMX-001 Against Systemic Cowpox Virus Infections in Mice (2007) (0)
Smallpox – still a concern (2018) (0)
AN ABSTRACT OF THE THESIS OF Christine A. Schneider for the degree of Honors Baccalaureate of Science in Biochemistry and Biophysics presented on May 26, 2011. Title: Investigations into the Mechanism of Action of Lead Dengue Virus Inhibitors (2011) (0)
Vaccinia virus: a novel approach for molecular engineering of peptide vaccines. (1993) (0)
Techniques for the cell-free translation of viral RNA. (1982) (0)
Abstracts of papers presented at the 6th Workshop on Poxvirus/Iridovirus, September 24-September 28 (1986) (0)
Use of Gram-positive bacteria as vaccine vectors (1998) (0)
[Frontiers in Bioscience 3, d354-364, March 22, 98] 354 BIOLOGY OF VACCINIA VIRUS ACYLPROTEINS (1998) (0)
Overview of the regulatory approval of tecovirimat intravenous formulation for treatment of smallpox: potential impact on smallpox outbreak response capabilities, and future tecovirimat development potential (2023) (0)
Case History: Tpoxx® (Tecovirimat)—A Novel Orthopoxvirus Egress Inhibitor for the Treatment of Smallpox (2020) (0)
Further characterization of an adenosine-containing modification of vaccinia virus proteins. (1993) (0)
Method of screening for antiviral against orthopoxvirus. (2003) (0)
Plots of mean plasma concentration versus time profiles in beagle dogs, following repeat oral administrations of ST-246 by gavage at a dose of 30 mg/kg seven consecutive days. (2013) (0)
Developing a drug for a disease that doesn?t exist: Arestvyr TM, a smallpox antiviral (2014) (0)
ST-246, a Therapeutic for Smallpox (2010) (0)
Small Molecule Inhibitors of Dengue Virus Replication are Active In Vivo (2010) (0)
Highlights on the mode of action of ST-246, an anti-orthopoxviral compound (2008) (0)
Nucleotide sequence and transcriptional studies of the vaccinia virus KpnI I DNA fragment. (1989) (0)
Title : Identification of Small Molecule Inhibitors of the Staphylococcus aureus Sortase (2008) (0)
Combinations of CMX-001 and ST-246 Synergistically Inhibit Orthopoxvirus Replication In Vitro (2007) (0)
Recombinant poxvirus and streptococcal vaccine containing protein m. (1990) (0)
Research Repor t BiZyme: A Novel Fusion Protein-Mediatin g Selection of Vaccinia Virus Recombinants b y Fluorescence and Antibiotic Resistanc e (2002) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Dennis E. Hruby?

Dennis E. Hruby is affiliated with the following schools:

Dennis E. Hruby's Academic­Influence.com Rankings

Dennis E. Hruby's Degrees

Why Is Dennis E. Hruby Influential?

Dennis E. Hruby's Published Works

Published Works

What Schools Are Affiliated With Dennis E. Hruby?

Dennis E. Hruby's AcademicInfluence.com Rankings